176 related articles for article (PubMed ID: 26826558)
1. Nanotechnology-based strategies for combating toxicity and resistance in melanoma therapy.
Brys AK; Gowda R; Loriaux DB; Robertson GP; Mosca PJ
Biotechnol Adv; 2016; 34(5):565-577. PubMed ID: 26826558
[TBL] [Abstract][Full Text] [Related]
2. New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies.
Azijli K; Stelloo E; Peters GJ; VAN DEN Eertwegh AJ
Anticancer Res; 2014 Apr; 34(4):1493-505. PubMed ID: 24692676
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in targeted nanoparticles drug delivery to melanoma.
Li J; Wang Y; Liang R; An X; Wang K; Shen G; Tu Y; Zhu J; Tao J
Nanomedicine; 2015 Apr; 11(3):769-94. PubMed ID: 25555352
[TBL] [Abstract][Full Text] [Related]
4. Recent developments in nanomedicine for melanoma treatment.
Tang JQ; Hou XY; Yang CS; Li YX; Xin Y; Guo WW; Wei ZP; Liu YQ; Jiang G
Int J Cancer; 2017 Aug; 141(4):646-653. PubMed ID: 28340496
[TBL] [Abstract][Full Text] [Related]
5. Advances in the management of melanoma: targeted therapy, immunotherapy and future directions.
Dean E; Lorigan P
Expert Rev Anticancer Ther; 2012 Nov; 12(11):1437-48. PubMed ID: 23249108
[TBL] [Abstract][Full Text] [Related]
6. Vemurafenib for the treatment of BRAF mutant metastatic melanoma.
Martin-Liberal J; Larkin J
Future Oncol; 2015; 11(4):579-89. PubMed ID: 25686114
[TBL] [Abstract][Full Text] [Related]
7. Nanotechnology-empowered strategies in treatment of skin cancer.
Chandra J; Hasan N; Nasir N; Wahab S; Thanikachalam PV; Sahebkar A; Ahmad FJ; Kesharwani P
Environ Res; 2023 Oct; 235():116649. PubMed ID: 37451568
[TBL] [Abstract][Full Text] [Related]
8. Targeted drug delivery to melanoma.
Liu Q; Das M; Liu Y; Huang L
Adv Drug Deliv Rev; 2018 Mar; 127():208-221. PubMed ID: 28939379
[TBL] [Abstract][Full Text] [Related]
9. A comprehensive review on novel targeted therapy methods and nanotechnology-based gene delivery systems in melanoma.
Rahimi A; Esmaeili Y; Dana N; Dabiri A; Rahimmanesh I; Jandaghian S; Vaseghi G; Shariati L; Zarrabi A; Haghjooy Javanmard S; Cordani M
Eur J Pharm Sci; 2023 Aug; 187():106476. PubMed ID: 37236377
[TBL] [Abstract][Full Text] [Related]
10. [Mechanisms of resistance to anti-BRAF treatments].
Charles J; Martel C; de Fraipont F; Leccia MT; Robert C; Busser B
Ann Dermatol Venereol; 2014 Nov; 141(11):671-81. PubMed ID: 25442471
[TBL] [Abstract][Full Text] [Related]
11. The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma.
Kim A; Cohen MS
Expert Opin Drug Discov; 2016 Sep; 11(9):907-16. PubMed ID: 27327499
[TBL] [Abstract][Full Text] [Related]
12. Nanomedicine Strategies for Management of Drug Resistance in Lung Cancer.
Haider M; Elsherbeny A; Pittalà V; Consoli V; Alghamdi MA; Hussain Z; Khoder G; Greish K
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163777
[TBL] [Abstract][Full Text] [Related]
13. CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations.
Camacho LH
Cancer Med; 2015 May; 4(5):661-72. PubMed ID: 25619164
[TBL] [Abstract][Full Text] [Related]
14. Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?
Welsh SJ; Rizos H; Scolyer RA; Long GV
Eur J Cancer; 2016 Jul; 62():76-85. PubMed ID: 27232329
[TBL] [Abstract][Full Text] [Related]
15. Nanocarrier-Based Drug Delivery for Melanoma Therapeutics.
Song M; Liu C; Chen S; Zhang W
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33668591
[TBL] [Abstract][Full Text] [Related]
16. Successes and setbacks of early investigational drugs for melanoma.
Orloff M; Valsecchi ME; Sato T
Expert Opin Investig Drugs; 2015; 24(8):993-7. PubMed ID: 26068553
[TBL] [Abstract][Full Text] [Related]
17. Integrating first-line treatment options into clinical practice: what's new in advanced melanoma?
Dummer R; Schadendorf D; Ascierto PA; Larkin J; Lebbé C; Hauschild A
Melanoma Res; 2015 Dec; 25(6):461-9. PubMed ID: 26426764
[TBL] [Abstract][Full Text] [Related]
18. Colon cancer therapy: recent developments in nanomedicine to improve the efficacy of conventional chemotherapeutic drugs.
Prados J; Melguizo C; Ortiz R; Perazzoli G; Cabeza L; Alvarez PJ; Rodriguez-Serrano F; Aranega A
Anticancer Agents Med Chem; 2013 Oct; 13(8):1204-16. PubMed ID: 23574385
[TBL] [Abstract][Full Text] [Related]
19. Current systemic therapies for melanoma.
Palathinkal DM; Sharma TR; Koon HB; Bordeaux JS
Dermatol Surg; 2014 Sep; 40(9):948-63. PubMed ID: 25072125
[TBL] [Abstract][Full Text] [Related]
20. Treatment algorithms in stage IV melanoma.
Espinosa E; Grob JJ; Dummer R; Rutkowski P; Robert C; Gogas H; Kefford R; Eggermont AM; Martin Algarra S; Hauschild A; Schadendorf D
Am J Ther; 2015; 22(1):61-7. PubMed ID: 24413374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
